BioCryst Pharma (BCRX) Misses Q1 EPS by 303c ; Offers Guidance

BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($2.98), $3.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $156.41 million versus the consensus estimate of $151.66 million.

GUIDANCE:

BioCryst Pharma sees FY2026 revenue of $635-660 million, versus the consensus of $650.2 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August